- Current report filing (8-K)
31 12월 2009 - 4:13AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported)
December 23, 2009
deCODE
genetics, Inc.
(Exact Name of
Registrant as Specified in Charter)
Delaware
|
|
000-30469
|
|
04-3326704
|
(State or Other Jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of Incorporation)
|
|
File Number)
|
|
Identification No.)
|
Sturlugata
8, IS-101 Reykjavík, Iceland
(Address of Principal Executive Offices)
Registrants telephone number, including area
code
+354-570-1900
(Former Name
or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
Item 3.01.
Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing.
On December 23,
2009 , deCODE genetics, Inc. (deCODE) received a notice from the Nasdaq
Stock Market (Nasdaq) stating that for 30 consecutive business days the
market value of the publicly held shares of its common stock had been below $15
million, the minimum level required for continued listing on The Nasdaq Global
Market as set forth in Nasdaq Listing Rule 5450(b)(3)(C). In accordance with Nasdaq Listing Rule 5810(c)(3)(D),
deCODE will be provided a period of 90 calendar days in which to regain
compliance. If at any time during this period, the market value of the publicly
held shares of deCODEs common stock is $15 million or more for a minimum of 10
consecutive business days, Nasdaq will provide deCODE with written confirmation
of compliance and the matter will be closed.
As previously reported
deCODE has appealed the potential suspension of trading in its common stock and
the subsequent delisting from Nasdaq pursuant to a notice from Nasdaq received
on November 18, 2009. A decision in
this matter is expected in January, 2010.
Item 5.02
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
Axel Nielsen, deCODEs chief operating
officer has advised deCODE that he will resign from such position effective January 1,
2010.
Item 7.01
Regulation FD Disclosure
The following dates relevant to deCODEs proceeding under Chapter 11 of the U.S.
Bankruptcy Code have been established:
January 12, 2010:
|
|
Auction of certain assets of deCODE genetics, Inc. (the
Purchased Assets) to parties submitting qualifying bids
|
|
|
|
January 14, 2010:
|
|
Hearing before the bankruptcy court to approve the sale of the
Purchased Assets
|
2
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
deCODE genetics, Inc.
|
|
|
|
|
|
By:
|
/s/ Kari Stefansson
|
|
|
Kari Stefansson
|
|
|
President, Chief Executive Officer
|
|
|
|
|
|
|
Dated: December 30, 2009
|
|
3
Decode Genetics (MM) (NASDAQ:DCGN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Decode Genetics (MM) (NASDAQ:DCGN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024